EANS-News: Epigenomics AG invites to Annual Press Conference and Analyst Meeting 2010
Berlin, Germany, and Seattle, WA, USA, March 25, 2010 (euro adhoc) -
Not for distribution in the United States of America
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Company Information/Molecular diagnostics
Subtitle: Not for distribution in the United States of America
Epigenomics AG (Frankfurt Prime Standard: ECX), invites media representatives, analysts and shareholders to this year's Annual Press Conference and Analyst Meeting on Monday, April 19, 2010 at 11:00 am (CET) at the premises of Villa Bonn in Frankfurt am Main, Germany. The conference will be held in German language. On the same day at 3:00 pm (CET)/9 am (EST) Epigenomics' management will host an Analyst Conference Call conducted in English language.
Please note that the events were originally planned for March 31, 2010 but due to the company's ongoing capital increase and the legal requirements and restrictions in external communication that go along with this had to be rescheduled to April 19, 2010. Epigenomics would like to thank you for your understanding and is looking forward to welcoming you at these events.
The Annual Report will be released on March 31, 2010 as originally planned.
Further Information
The annual report 2009 will be available at Epigenomics' website from March 31, 2010 at: www.epigenomics.com/en/investor_relations/Financial_Information/
Epigenomics will host the Annual Press Conference and Analyst Meeting in German language on April 19, 2010 at 11 am CET at the premises of the Villa Bonn - Frankfurter Gesellschaft für Handel Industrie und Wirtschaft in Frankfurt am Main:
Villa Bonn Frankfurter Gesellschaft für Handel Industrie und Wirtschaft Siesmayerstrasse 12 60323 Frankfurt am Main Room: Vortragsraum (OG)
An Analyst Conference Call will be hosted by Epigenomics' management on the same day at 3 pm (CET)/9 am (EST). The conference call will be conducted in English.
Dial-in number (within Germany.): +49 (0) 69 247 501 899 Dial-in number (outside Germany): +1 212 444 0297
Please dial-in at least 10 minutes prior to the start of the call.
To follow the presentation, we kindly ask all participants of the call to download the slide set from the company website prior to the call where it will be made available as a PDF file at 11 am CET (5 am EST) on the same day via: www.epigenomics.com/en/down_loads/corporate_material/
The conference call will be recorded and also made available on the company website web as a audio file after the call. Please go to: www.epigenomics.com/en/down_loads/corporate_material/
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests on the market and in development aim at diagnosing cancer at an early stage before symptoms occur and thereby may reduce mortality from this dreaded disease.
Epigenomics' product portfolio contains the CE-marked IVD test Epi proColon, the world's first regulatory cleared molecular diagnostic test for the detection of colorectal cancer in blood that is based on the biomarker Septin9, and further proprietary DNA methylation biomarkers and IVD products at various stages of development for colorectal, lung and prostate cancer. For development and global commercialization of IVD test products, Epigenomics pursues a dual business strategy in which direct commercialization of proprietary diagnostic test products is combined with non-exclusive licensing to diagnostic industry players with broad customer access. Strategic diagnostics industry partners include Abbott Molecular, Sysmex Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories, Inc. for diagnostics test products and services, and QIAGEN N.V. for sample preparation solutions and research products. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary, Epigenomics Inc., in Seattle, WA, U.S.A. For more information, please visit Epigenomics' website at www.epigenomics.com.
Epigenomics legal disclaimers. This publication is not an offer of any securities for sale or a solicitation of an offer to purchase any securities. Any offer of shares will only be made by and on the basis of a prospectus to be published. This document is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares of Epigenomics AG (the "Shares") have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the Shares in the United States and the Shares will not be registered under the Securities Act. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
end of announcement euro adhoc
Further inquiry note:
Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com
Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade